Cyclacel Pharmaceuticals Inc (CYCC)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Spiro Rombotis
Employees:
14
200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ, 07922
908-517-7330
-
Formally known as:
- Xcyte Therapies Inc.
Date | Ratio |
---|---|
2006-03-27 | 1:1 |
2012-08-27 | 1:7 |
2016-05-31 | 1:12 |
2020-04-15 | 1:20 |
2023-12-18 | 1:15 |
Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|